HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.
Speaker at International Alzheimer’s Disease & Dementia Conference 2022 - Subramanian Boopathi
Universidad Nacional Autónoma de México, Mexico
Title : Characterization of a New molecules’ inhibitor effect on Alzheimer’s Disease Amyloid-Beta Peptides Cascade


Over 50 million people succumbed to Alzheimer’s disease (AD) worldwide. Unless scientists predict effective therapeutic strategies, this number will reach 150 million by 2050. AD is characterized by progressive neurodegeneration associated with Amyloid β (Aβ) plaques constituted by the aggregated Aβ peptides, which are produced from the transmembrane Amyloid precursor protein (APP) after being cleaved by β- and γ-secretases. In the case of the healthy brain, Aβ peptides are in monomeric forms soluble in water and are involved in brain development and protect neurons from excitotoxic cell death. In contrast, in the case of AD-affected brain, the peptides aggregate into soluble oligomers and then insoluble fibrils resulting in the formation of plaques, causing neuronal cell death and cognitive impairment such as memory loss, communication difficulties, and personality changes. Since, Aβ oligomers induced toxicity to neurons, in the present talk, I will discuss an overview of the mechanism of AD development, and how our discovery of molecule assists to improve the cognitive ability of AD mice by employing an array of studies of in-silico, in-vitro and in-vivo studies. 

Keywords: Alzheimer’s Disease, Amyloid peptide, drug, and AD mice.


What will the audience learn from your presentation?

  • Audience learns the mechanism of Alzheimer’s disease development
  • Audience will be benefitted by gaining knowledge of Alzheimer’s disease features and drugs for the treatment of the disease, and why it will affect senior adult populations.
  • We characterized new molecules that improve the cognitive ability of AD-affected mice by stopping the killing neurons by Alzheimer’s peptide.


Dr. Subramanian Boopathi obtained a Ph.D. degree in Physics from Bharathiar University in 2016, and he has worked with Professor P. Kolandaivel’s mentorship on Alzheimer's disease (AD) research. After that, he completed a three-year postdoctoral: one year (2016–2017) in Prof. Sihyun Ham's group at Sookmyung women's university, South Korea, and two-year (2018–2020) in Prof. Wendy Gonzalez's group at the University of Talca, Chile. Subsequently, he moved to Professor Mai Suan Li's lab at the Institute of Physics Polish Academy Science, Poland, and carried out a scientific work for six months (2018). Now, he is pursuing a third postdoctoral under the supervision of R.G.J at the University of National Autonomous of Mexico. His main field of research focuses on the intriguing feature of Alzheimer's amyloid peptide aggregation in the membrane by computer simulations. He has ten years of research in AD. He has published 18 research articles in SCI journals.